Literature DB >> 14581314

Latent tuberculosis: revised treatment guidelines.

Erica Weir1, David N Fisman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14581314      PMCID： PMC219630     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  14 in total

Review 1.  Tuberculosis: 9. Treatment.

Authors:  E Hershfield
Journal:  CMAJ       Date:  1999-08-24       Impact factor: 8.262

Review 2.  Tuberculosis: 12. Global disease and the role of international collaboration.

Authors:  D A Enarson
Journal:  CMAJ       Date:  2000-01-11       Impact factor: 8.262

3.  Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States.

Authors:  Kamran Khan; Peter Muennig; Maryam Behta; Joshua Graff Zivin
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

4.  The case against anergy testing as a routine adjunct to tuberculin skin testing.

Authors:  B S Slovis; J D Plitman; D W Haas
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

5.  Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida.

Authors:  Masahiro Narita; Michael Kellman; Diana L Franchini; Marie E McMillan; Elena S Hollender; David Ashkin
Journal:  Chest       Date:  2002-10       Impact factor: 9.410

6.  Outcomes of contact investigations of infectious tuberculosis patients.

Authors:  S M Marks; Z Taylor; N L Qualls; R J Shrestha-Kuwahara; M A Wilce; C H Nguyen
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

7.  Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.

Authors:  N A Halsey; J S Coberly; J Desormeaux; P Losikoff; J Atkinson; L H Moulton; M Contave; M Johnson; H Davis; L Geiter; E Johnson; R Huebner; R Boulos; R E Chaisson
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

8.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

10.  Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-08-08       Impact factor: 17.586
View more
  2 in total

1.  Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction.

Authors:  Omar Khokhar; Christopher Gange; Stephen Clement; James Lewis
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

2.  The risk of tuberculosis transmission in solid organ transplantation: Is it more than a theoretical concern?

Authors:  Gregory Rose
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-09       Impact factor: 2.471
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.